MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast

Suash Sharma, M. Hossein Saboorian, William H. Frawley, Eugene P. Frenkel, Barbara B. Haley, Raheela Ashfaq

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In this study, we determined the extent of variation in proliferative markers and hormone receptor status in breast carcinoma between core biopsies and subsequent resections, and determined the impact of clinical and histologic parameters on such variation. We performed a paired comparison of biomarkers in 87 core biopsies and subsequent resections of breast carcinomas in patients with and without preoperative chemotherapy. The markers included estrogen receptor, progesterone receptor, Her2/neu, DNA ploidy (diploidy versus nondiploidy), DNA index (difference of ≥0.5), and MIB1 labeling index (<15% vs. >15%). The tumor biomarkers were evaluated with standard IHC and scored by automated cellular imaging systems. The number of patients showing prominent changes were as follows: ploidy, 12; DI, 15; ER, 6; PR, 15; MIB1, 17; and Her2/neu, 15. Seventeen of 87 patients sustained a significant change in MIB1 index (above or below 15%). The patients who received chemotherapy had a larger proportion with a change in MIB1 status (P < 0.05). DI showed a similar trend, although it was not statistically significant. Of the patients with MIB1 values higher in biopsy specimens, a majority showed values to decrease below 15%. MIB1 index reduction by greater than 25% was seen in 8 of 16 (50%) cases with chemotherapy, compared with only 3 of 32 (9%) without chemotherapy. MIB1 and DNA index values postchemotherapy can be a useful measure of chemoresponse. Our study underscores the need to perform prognostic markers on both biopsy and subsequent resections, especially in the setting of preoperative chemotherapy.

Original languageEnglish (US)
Pages (from-to)290-295
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume12
Issue number4
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Biopsy
Ploidies
DNA
Matched-Pair Analysis
Progesterone Receptors
Tumor Biomarkers
Diploidy
Estrogen Receptors
Biomarkers
Hormones

Keywords

  • Breast
  • Carcinoma
  • Chemotherapy
  • Immunohistochemistry
  • MIB1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast. / Sharma, Suash; Saboorian, M. Hossein; Frawley, William H.; Frenkel, Eugene P.; Haley, Barbara B.; Ashfaq, Raheela.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 12, No. 4, 01.01.2004, p. 290-295.

Research output: Contribution to journalArticle

Sharma, Suash ; Saboorian, M. Hossein ; Frawley, William H. ; Frenkel, Eugene P. ; Haley, Barbara B. ; Ashfaq, Raheela. / MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast. In: Applied Immunohistochemistry and Molecular Morphology. 2004 ; Vol. 12, No. 4. pp. 290-295.
@article{4e87c8ebc30a4b9eaf9271c795edf73a,
title = "MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast",
abstract = "In this study, we determined the extent of variation in proliferative markers and hormone receptor status in breast carcinoma between core biopsies and subsequent resections, and determined the impact of clinical and histologic parameters on such variation. We performed a paired comparison of biomarkers in 87 core biopsies and subsequent resections of breast carcinomas in patients with and without preoperative chemotherapy. The markers included estrogen receptor, progesterone receptor, Her2/neu, DNA ploidy (diploidy versus nondiploidy), DNA index (difference of ≥0.5), and MIB1 labeling index (<15{\%} vs. >15{\%}). The tumor biomarkers were evaluated with standard IHC and scored by automated cellular imaging systems. The number of patients showing prominent changes were as follows: ploidy, 12; DI, 15; ER, 6; PR, 15; MIB1, 17; and Her2/neu, 15. Seventeen of 87 patients sustained a significant change in MIB1 index (above or below 15{\%}). The patients who received chemotherapy had a larger proportion with a change in MIB1 status (P < 0.05). DI showed a similar trend, although it was not statistically significant. Of the patients with MIB1 values higher in biopsy specimens, a majority showed values to decrease below 15{\%}. MIB1 index reduction by greater than 25{\%} was seen in 8 of 16 (50{\%}) cases with chemotherapy, compared with only 3 of 32 (9{\%}) without chemotherapy. MIB1 and DNA index values postchemotherapy can be a useful measure of chemoresponse. Our study underscores the need to perform prognostic markers on both biopsy and subsequent resections, especially in the setting of preoperative chemotherapy.",
keywords = "Breast, Carcinoma, Chemotherapy, Immunohistochemistry, MIB1",
author = "Suash Sharma and Saboorian, {M. Hossein} and Frawley, {William H.} and Frenkel, {Eugene P.} and Haley, {Barbara B.} and Raheela Ashfaq",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/00129039-200412000-00002",
language = "English (US)",
volume = "12",
pages = "290--295",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast

AU - Sharma, Suash

AU - Saboorian, M. Hossein

AU - Frawley, William H.

AU - Frenkel, Eugene P.

AU - Haley, Barbara B.

AU - Ashfaq, Raheela

PY - 2004/1/1

Y1 - 2004/1/1

N2 - In this study, we determined the extent of variation in proliferative markers and hormone receptor status in breast carcinoma between core biopsies and subsequent resections, and determined the impact of clinical and histologic parameters on such variation. We performed a paired comparison of biomarkers in 87 core biopsies and subsequent resections of breast carcinomas in patients with and without preoperative chemotherapy. The markers included estrogen receptor, progesterone receptor, Her2/neu, DNA ploidy (diploidy versus nondiploidy), DNA index (difference of ≥0.5), and MIB1 labeling index (<15% vs. >15%). The tumor biomarkers were evaluated with standard IHC and scored by automated cellular imaging systems. The number of patients showing prominent changes were as follows: ploidy, 12; DI, 15; ER, 6; PR, 15; MIB1, 17; and Her2/neu, 15. Seventeen of 87 patients sustained a significant change in MIB1 index (above or below 15%). The patients who received chemotherapy had a larger proportion with a change in MIB1 status (P < 0.05). DI showed a similar trend, although it was not statistically significant. Of the patients with MIB1 values higher in biopsy specimens, a majority showed values to decrease below 15%. MIB1 index reduction by greater than 25% was seen in 8 of 16 (50%) cases with chemotherapy, compared with only 3 of 32 (9%) without chemotherapy. MIB1 and DNA index values postchemotherapy can be a useful measure of chemoresponse. Our study underscores the need to perform prognostic markers on both biopsy and subsequent resections, especially in the setting of preoperative chemotherapy.

AB - In this study, we determined the extent of variation in proliferative markers and hormone receptor status in breast carcinoma between core biopsies and subsequent resections, and determined the impact of clinical and histologic parameters on such variation. We performed a paired comparison of biomarkers in 87 core biopsies and subsequent resections of breast carcinomas in patients with and without preoperative chemotherapy. The markers included estrogen receptor, progesterone receptor, Her2/neu, DNA ploidy (diploidy versus nondiploidy), DNA index (difference of ≥0.5), and MIB1 labeling index (<15% vs. >15%). The tumor biomarkers were evaluated with standard IHC and scored by automated cellular imaging systems. The number of patients showing prominent changes were as follows: ploidy, 12; DI, 15; ER, 6; PR, 15; MIB1, 17; and Her2/neu, 15. Seventeen of 87 patients sustained a significant change in MIB1 index (above or below 15%). The patients who received chemotherapy had a larger proportion with a change in MIB1 status (P < 0.05). DI showed a similar trend, although it was not statistically significant. Of the patients with MIB1 values higher in biopsy specimens, a majority showed values to decrease below 15%. MIB1 index reduction by greater than 25% was seen in 8 of 16 (50%) cases with chemotherapy, compared with only 3 of 32 (9%) without chemotherapy. MIB1 and DNA index values postchemotherapy can be a useful measure of chemoresponse. Our study underscores the need to perform prognostic markers on both biopsy and subsequent resections, especially in the setting of preoperative chemotherapy.

KW - Breast

KW - Carcinoma

KW - Chemotherapy

KW - Immunohistochemistry

KW - MIB1

UR - http://www.scopus.com/inward/record.url?scp=10044292936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044292936&partnerID=8YFLogxK

U2 - 10.1097/00129039-200412000-00002

DO - 10.1097/00129039-200412000-00002

M3 - Article

C2 - 15536327

AN - SCOPUS:10044292936

VL - 12

SP - 290

EP - 295

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 4

ER -